Q-omics provides the consensus-scored B3GAT1 profile across patient tissues and cancer cell-line models. B3GAT1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, B3GAT1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, B3GAT1 RNA expression shows 15,737 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight MESO, THCA, and PCPG as cancer lineages where B3GAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GAT1 survival associations across molecular data types. B3GAT1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GAT1 RNA expression–survival associations across cancer types. High B3GAT1 expression shows unfavorable associations in MESO and LUSC, but favorable associations in HNSC, CESC, PAAD and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify MESO as the clearest survival context for B3GAT1 RNA expression.
This table summarizes B3GAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for B3GAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GAT1 shows lower tumor expression in KICH, LUSC and BRCA and higher tumor expression in THCA, PRAD and KIRP. The THCA box plot shows higher B3GAT1 RNA expression in tumor versus normal tissue (log2 FC = +2.247, t-test p < 0.001).
This table shows molecular features associated with B3GAT1 in patient tissues and cancer cell lines. In patient samples, B3GAT1 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
